Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant systemic therapy for recurrent colorectal liver metastases
NCT05861505Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2023
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, capecitabine, fluorouracil, folinic acid, irinotecan and 1 more in Colorectal cancer with liver metastases (CRLM) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Overall Survival at 5 years. Started Apr 2023; status: recruiting.
02
Drugs
oxaliplatincapecitabinefluorouracilfolinic acidirinotecan
03
Conditions
Colorectal cancer with liver metastases (CRLM)
Beyond the preview
Go deeper on NCT05861505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861505.